TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02860273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula Oxygen
Description: Exercise capacity testing according to High Flow Nasal Cannula Oxygen at 21% in COPD patients involved in a Pulmonary Rehabilitation program.

Intervention type: DEVICE
Group type: OTHER
Intervention: Treadmill
Description: Exercise capacity testing in COPD patients involved in a Pulmonary Rehabilitation Program.
Study: NCT02375646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMW Heparin
Study: NCT01518621

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Whole brain radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation plus erlotinib
Description: Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
Study: NCT03412461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thought Spot
Description: Thought Spot is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resource Pamphlet
Description: The resource pamphlet that participants will be given will include information on the mental health and wellness services available at their respective post-secondary institution.
Study: NCT01875991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept via Autoinjector A
Description: Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept via Autoinjector B
Description: Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
Study: NCT03380182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure Band
Description: These bands use pressure to stimulate the P6 acupuncture point.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Band
Description: These sham bands are used to make it seem like the band is using pressure to stimulate the P6 acupuncture point.
Study: NCT03679312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Study: NCT01445431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil
Description: Virgin coconut oil applied to the test site twice daily for four weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Oil
Description: Mineral oil applied to the test site twice daily for four weeks
Study: NCT01836003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tokafatso programmatic intervention
Description: Tokafatso programmatic intervention:~* SMS-based platform for delivery of CD4 test results~* Participatory educational session for clinic staff~* Loan program for HIV and CD4 testing supplies~* Facilitation of tracing of HAART-eligible pregnant women
Study: NCT05292430

Intervention type: OTHER
Intervention: Specimen Collection
Description: collection of diseased and non-diseased tissue, blood, and other body fluids
Study: NCT02190344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8-channel paddle coil
Description: MRI Coil
Study: NCT02454322

Intervention type: DRUG
Intervention: Magnesium Sulfate
Description: Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
Study: NCT02837263

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.~SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Study: NCT05974865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Babies and Healthy Moms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baby Basics Prenatal Guide
Study: NCT02488473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 100 ug dexmedetomidine added to the ropivacaine nerveblock

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20 ml Ropivacaine 5mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 20 ml Ropivacaine 5mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: Placebo
Study: NCT04390035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction using Delfi Personalized Tourniquet System
Description: Participants assigned to the test group will undergo blood flow restriction training 2 days per week beginning at week 1-2 post-surgery and continuing through week 16 post-surgery using the FDA-approved Delfi Personalized Tourniquet System (PTS) with personalized pressure of 80% of the limb occlusion pressure (LOP). The LOP is the amount of pressure required to fully occlude arterial and venous blood flow to the limb. Otherwise, both the test group and control group will follow a standard 6-month post-surgery rehabilitation protocol which is standard of care for ACLR recovery.
Study: NCT02287506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimised Diagnostic Strategy
Description: (ODS) based on integrating Clinical information (a validated clinical probability model), Biomarkers (GAD, IA2 and ZnT8 autoantibodies) and Genetic testing for MODY
Study: NCT02307188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constellation Full Contact Mapping Catheter
Description: 64-electrode intracardiac mapping catheter.
Study: NCT00734617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Groups 1 \& 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day~Groups 2 \& 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Groups 1 \& 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day~Groups 2 \& 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day
Study: NCT05094986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial Medication Adherence (IMA) Intervention
Description: The IMA intervention promotes health literacy and patient participation in the decision-making process during the recommendation and prescription of a new drug for the management of cardiovascular disease and diabetes. The IMA intervention has four main components: 1. Training for healthcare professionals (GPs, nurses, and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; 2. Intervention support tools; decision aids (leaflets and website) and implementation tools (dispensing alert in community pharmacies when dispensing insulins and antiplatelet drugs); 3. Shared decision-making process during the GP's consultation; and 4. Information support provided by the nurses and community pharmacists that use the intervention decision aids to explore the patients' doubts and standardise the discourse between primary healthcare professionals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients received the usual care when being prescribed a new prescription for treatments of cardiovascular disease or diabetes. Nurses and community pharmacists were asked to also provide usual care to those patients. Community pharmacists from the control group had the dispensing alert available when dispensing insulins and antiplatelet drugs.
Study: NCT02198755

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hitachi-Aloka Noblus ultrasound scanner
Description: High resolution ultrasound with the Hitachi-Aloka Noblus Scanner and a 8-15mHz transducer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI with or without contrast
Study: NCT03406832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroprusside Sodium
Description: Intracoronary infusion 50\~100μg each time (repeated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban Hydrochloride
Description: Intracoronary infusion 10μg/kg for single time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparinized saline
Description: Intracoronary infusion 2ml for single time
Study: NCT02460315

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early cholecystectomy
Description: Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 1 will be managed by early laparoscopic cholecystectomy (LC) within 3 days after ERCP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: late cholecystectomy
Description: Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 2 will be managed by late LC one month after ERCP.
Study: NCT02120859

Intervention type: DEVICE
Group type: OTHER
Intervention: FFR - guided DEB angioplasty
Description: DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (\> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis \< 40% and FFR \> 0.8.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR - guided DEB angioplasty
Description: DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (\> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis \< 40% and FFR \> 0.8.

Intervention type: DEVICE
Group type: OTHER
Intervention: Provisional bare metal stenting
Description: In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
Study: NCT00842894

Intervention type: DRUG
Intervention: insulin detemir
Description: Safety and effectiveness data collection in connection with the use of the drug.

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
Study: NCT05114018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasteurized A. muciniphila
Description: Daily oral dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo = identical to verum regarding the form, size, taste, color and intake
Study: NCT00291330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate 150 mg
Description: twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin (INR 2-3)
Description: prn to maintain INR (2-3)
Study: NCT04822428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulation
Description: Osteopathic manipulative techniques including; suboccipital release technique,sacral release technique, diaphragmatic release, mesentery release, and Colonic manipulation
Study: NCT03849079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyponut
Description: Prick tests with hyponut
Study: NCT03233373

Intervention type: DEVICE
Intervention: Seek CompactPro thermal imager
Description: A device with image/video recording capability, it is non-invasive and only relies on infrared emissions from heat sources (the patient).
Study: NCT01445873

Intervention type: DRUG
Intervention: Sitaxentan sodium
Description: Sitaxentan sodium 100 mg / day
Study: NCT02754180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TS-1 with radiation
Description: gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
Study: NCT05103488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive palliative care
Description: CPC is multidisciplinary inpatient care that aims to respond to patients' suffering in many aspects: physical, psychological, social, and spiritual. It is basically a standard palliative care service in Vietnam with additional psychosocial and spiritual support with a multidisciplinary approach.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Patients who are randomized to the control group will receive the standard palliative care in Vietnam. They can assess to the same palliative care for their physical symptoms as patients in the intervention group do. They can also access psychosocial and spiritual support from the resources that available for them before entering to the study. If they request for social or financial support, their care team can reach out to the social work departments. Patients who are in need can receive mental health care from psychiatrists from the psychiatrist unit at UMC.
Study: NCT01963221

Intervention type: RADIATION
Group type: OTHER
Intervention: fludeoxyglucose(18f)

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: cardiac and aortic magnetic resonance imaging

Intervention type: OTHER
Group type: OTHER
Intervention: carotid femoral pulse wave velocity

Intervention type: RADIATION
Group type: OTHER
Intervention: positron emission tomography

Intervention type: RADIATION
Group type: OTHER
Intervention: computed tomography
Study: NCT01841398

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimedia Lifestyle Improvement
Description: * Goal setting to improve diet, physical activity or smoking behaviours~* Regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
Study: NCT02717936

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Immunohistochemistry using Pancytokeratin Staining
Study: NCT02623309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic (Allo) hematopoietic stem cell transplantation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic (Allo) hematopoietic stem cell transplantation
Study: NCT03663205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously
Study: NCT03579979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Subcutaneous injection of injection point at the periphery of the areola or tumor, injecting 1% methylene blue 0.5ml at each point, a total of 2-3 points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Within 5 minutes after MB injection, 2.5mg/ml ICG 0.5ml was injected at each point, a total of 2-3 points. Methylene blue and ICG injection points do not coincide
Study: NCT02162134

Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Midazolam 0.7mg/kg 45 min before surgery
Description: Inj . Midazolam 0.7 mg/kg given as premedication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Midazolam 0.7mg/kg 45 min before surgery
Description: Inj . Midazolam 0.7 mg/kg given as premedication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Midazolam 0.7mg/kg 45 min before surgery
Description: Inj . Midazolam 0.7 mg/kg given as premedication.

Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Propofol 2.5mg/kg
Description: It was given to induce anesthesia after 3 min of pre oxygenation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Propofol 2.5mg/kg
Description: It was given to induce anesthesia after 3 min of pre oxygenation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Propofol 2.5mg/kg
Description: It was given to induce anesthesia after 3 min of pre oxygenation.

Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Atracurium 0.5 mg/kg
Description: It was given to induce muscle relaxation during anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Atracurium 0.5 mg/kg
Description: It was given to induce muscle relaxation during anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Atracurium 0.5 mg/kg
Description: It was given to induce muscle relaxation during anesthesia.

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane 2.5 vol %
Description: It was given to maintain anesthesia during surgery alongwith oxygen in air mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2.5 vol %
Description: It was given to maintain anesthesia during surgery alongwith oxygen in air mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2.5 vol %
Description: It was given to maintain anesthesia during surgery alongwith oxygen in air mixture

Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Cefuroxime 1.5 g IV
Description: It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Cefuroxime 1.5 g IV
Description: It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Cefuroxime 1.5 g IV
Description: It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery

Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Ketorolac 30 mg IV
Description: 3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
Study: NCT03663205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously
Study: NCT03593772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mission Reconnect
Description: This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mission Reconnect
Description: This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
Study: NCT03284866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given IM